The aim of this study was to develop a technology for producing a high-protein feed product from white lupine, followed by an assessment of its protein content. Dega white lupine (Ivanovo, Russia, 2024 harvest) was used in this study. The seeds were crushed, subjected to various pre-treatment regimes, and then to enzymatic hydrolysis with preparations of Ferment Group of Companies (Belarus) at t = 50°C, 130 min-1, pH = 4.5-5.0 for 10 hours. The enzyme composition that allowed obtaining the maximum yield of reducing substances was determined experimentally using a complete three-factor design (factor X1 is the dosage of the cellulase complex, 0.005-0.4% of the substrate in the raw material, X2 is the dosage of hemicellulases, 0.33-3.0%, X3 is the dosage of lipase, 0.06-0.4%, response Y1 is the concentration of reducing substances in % in hydrolysates). Candida tropicalis VKPM Y-3 and Saccharomyces cerevisiae VKPM Y-1136 yeasts were cultured in a mixture of solid products and hydrolysates at 28-35°C, 90 min-1, and pH 4.8-5.0 for 24 hours. After drying, the final fermented product was ground and its crude protein content was determined. The resulting concentrate contained 47.2 ± 1.12% crude protein (during fermentation with Candida tropicalis yeast) and 44.9 ± 1.33% (with Saccharomyces cerevisiae), demonstrating the high efficiency of developed technology for enriching the product with protein. This is the first technology for two-stage bioconversion of lupine seeds in the liquid phase using the “enzymatic hydrolysis - yeast cultivation” scheme, ensuring targeted hydrolysis of polysaccharides while preserving protein fractions.
No takes yet. Share an insight, caveat, or question.
Просвирников et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: